Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$9.19 USD
-0.20 (-2.13%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.21 +0.02 (0.22%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 5/9/24 |
---|---|
Current Quarter | -1.30 |
EPS Last Quarter | -2.30 |
Last EPS Surprise | 17.86% |
ABR | 1.33 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -5.18 |
Next Year | -5.47 |
EPS (TTM) | -11.60 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 3.60M | 0.00M | 3.60M | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -1.30 | -1.20 | -5.18 | -5.47 |
# of Estimates | 2 | 1 | 4 | 3 |
Most Recent Consensus | NA | NA | -4.90 | NA |
High Estimate | -1.20 | -1.20 | -4.80 | -4.90 |
Low Estimate | -1.40 | -1.20 | -6.01 | -6.00 |
Year ago EPS | -2.90 | -3.10 | -11.60 | -5.18 |
Year over Year Growth Est. | 55.17% | 61.29% | 55.34% | -5.58% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 1 | 1 | 4 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 0 | 0 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -1.30 | -1.20 | -5.18 | -5.47 |
7 Days Ago | -1.30 | -1.20 | -5.18 | -5.47 |
30 Days Ago | -1.30 | -1.20 | -5.18 | -5.47 |
60 Days Ago | -3.30 | -1.80 | -7.73 | -5.50 |
90 Days Ago | -3.30 | -1.80 | -8.73 | -11.00 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -1.30 | -1.20 | -6.01 | -4.90 |
Zacks Consensus Estimate | -1.30 | -1.20 | -5.18 | -5.47 |
Earnings ESP | 0.00% | 0.00% | -16.08% | 10.37% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -2.30 | -3.30 | -3.10 | -2.90 | NA |
Estimate | -2.80 | -3.00 | -3.20 | -3.00 | NA |
Difference | 0.50 | -0.30 | 0.10 | 0.10 | 0.10 |
Surprise | 17.86% | -10.00% | 3.12% | 3.33% | 3.58% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more